Prostratin (Synonyms: 13-O-Acetylphorbol) |
| Catalog No.GC44729 |
An HIV reactivator
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 60857-08-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Activation of latent reservoirs of HIV-infected cells is a treatment strategy designed to reduce viral load and eliminate the perpetuation of retroviral infection. Prostratin is a non-tumor promoting phorbol ester that potently induces HIV-1 reactivation in latent reservoirs of infected Jurkat-LAT-GFP cells with an IC50 value of ~0.5 µM. [1] Originally, prostratin was isolated from plant sources including P. prostrata, E. cornigera, and H. nutans. [2] The effects of prostratin are mediated through activation of NF-κB via protein kinase C and by downregulation of HIV-1 receptor CD4 expression and its co-receptors CXCR4 and CCR5.[3][4][5]
Reference:
[1]. Bedoya, L.M., Márquez, N., Martínez, N., et al. SJ23B, a jatrophane diterpene activates classical PKCs and displays strong activity against HIV in vivo. Biochemical Pharmacology 77, 965-978 (2009).
[2]. Wender, P.A., Kee, J.M., and Warrington, J.M. Practical synthesis of prostratin, DPP, and their analogs, adjuvant leads against latent HIV. Science 320, 649-652 (2008).
[3]. Williams, S.A., Chen, L.F., Kwon, H., et al. Prostratin antagonizes HIV latency by activating NF- k B. The Journal of Biological Chemisty 279(40), 42008-42017 (2004).
[4]. Biancotto, A., Grivel, J.C., Gondois-Rey, F., et al. Dual role of prostratin in inhibition of infection and reactivation of human immunodeficiency virus from latency in primary blood lymphocytes and lymphoid tissue. Journal of Virology 78(19), 10507-10515 (2004).
[5]. Hezareh, M., Moukil, M.A., Szanto, I., et al. Mechanisms of HIV receptor and co-receptor down-regulation by prostratin: Role of conventional and novel PKC isoforms. Antivir. Chem. Chemother. 15, 207-222 (2004).
| Cas No. | 60857-08-1 | SDF | |
| Synonyms | 13-O-Acetylphorbol | ||
| Chemical Name | 9a-(acetyloxy)-1,1aR,1bS,4,4aR,7aS,7bR,8R,9,9aS-decahydro-4a,7b-dihydro-3-(hydroxymethyl)-1,1,6,8-tetramethyl-5H-cyclopropa[3,4]benz[1,2-e]azulen-5-one | ||
| Canonical SMILES | OCC1=C[C@H]2[C@H]3[C@@](OC(=O)C)(C[C@@H](C)C2(O)C2C=C(C)C(=O)[C@@]2(O)C1)C3(C)C | ||
| Formula | C22H30O6 | M.Wt | 390.5 |
| Solubility | 10mg/mL in DMSO,10mg/mL in DMF, 10mg/mL in Ethanol | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5608 mL | 12.8041 mL | 25.6082 mL |
| 5 mM | 0.5122 mL | 2.5608 mL | 5.1216 mL |
| 10 mM | 0.2561 mL | 1.2804 mL | 2.5608 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 6 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *